Therapeutic drug management: Is it the future of multidrug-resistant tuberculosis treatment?

European Respiratory Journal

Volumn 42, Issue 6, 2013, Pages 1449-1453

  Srivastava, Shashikant ^a   Peloquin, Charles A ^b   Sotgiu, Giovanni ^c   Migliori, Giovanni Battista ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF SASSARI   (Italy)

^d IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ANTIVIRUS AGENT; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; RITONAVIR;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; COST OF ILLNESS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT INDICATION;

ACETAMIDES; ANTITUBERCULAR AGENTS; CLARITHROMYCIN; FEMALE; HUMANS; MALE; OXAZOLIDINONES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84890108607     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00073213     Document Type: Review

References (32)

1. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012; 379: 1902-1913.
2. Zumla A, Kim P, Maeurer M, et al. Zero deaths from tuberculosis: progress, reality, and hope. Lancet Infect Dis 2013; 13: 285-287.
3. World Health Organization. Global tuberculosis report 2012. Geneva, World Health Organization, 2012.
4. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
5. Migliori GB, Dara M, De Colombani P, et al. Multidrug-resistant tuberculosis in Eastern Europe: still on the increase? Eur Respir J 2012; 39: 1290-1291.
6. Migliori GB, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: E070517.1.
7. Udwadia Z, Vendoti D. Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining. J Epidemiol Community Health 2013; 67: 471-472.
8. Migliori GB, Centis R, D'Ambrosio L, et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin Infect Dis 2012; 54: 1379-1380.
9. World Health Organization. Drug-resistant tuberculosis. Frequently asked questions, 2012 www.who.int/tb/challenges/mdr/tdrfaqs/en/index.html Date last accessed: Apr 22, 2013. Date last updated: January 2012.
10. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
11. Floyd K, Hutubessy R, Kliiman K, et al. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J 2012; 40: 133-142.
12. Loddenkemper R, Sotgiu G, Mitnick CD. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J 2012; 40: 9-11.
13. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
14. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
15. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
16. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-151.
17. Bolhuis MS, van Altena R, van Soolingen D, et al. Clarithromycin increases linezolid exposure in multidrugresistant tuberculosis patients. Eur Respir J 2013; 42: 1614-1621.
18. Akkerman OW, van Altena R, Klinkenberg T, et al. Drug concentration in lung tissue in multidrug-resistant tuberculosis. Eur Respir J 2013; 42: 1750-1752.
19. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
20. Heysell SK, Moore JL, Keller SJ, et al. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerging Infect Dis 2010; 16: 1546-153.
21. Peloquin CA. Pharmacological issues in the treatment of tuberculosis. Ann N Y Acad Sci 2001; 953: 157-164.
22. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-2183.
23. Migliori GB, Sotgiu G, D'Ambrosio L, et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J 2012; 39: 619-625.
24. Raviglione MC, Lange C, Migliori GB. Preventing and managing antimicrobial resistance: imperative for chest physicians. Eur Respir J 2011; 37: 978-981.
25. Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951-1959.
26. Van der Werf MJ, Langendam MW, Huitric E, et al. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J 2012; 39: 1511-1519.
27. Tortoli E, Russo C, Piersimoni C, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012; 40: 442-447.
28. Garcia-Prats A, Donald P, Hesseling A, et al. Second-Line Antituberculosis Drugs in Children: A Commissioned Review for the World Health Organization 19th Expert Committee on the Selection and Use of Essential Medicines. www.who.int/selection-medicines/committees/expert/19/applications/TB- 624-C-R.pdf Date last accessed: January 2013. Date last updated: January 2013.
29. Vu DH, Alffenaar JWC, Edelbroek PM, et al. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des 2011; 17: 2931-2939.
30. Fattorini L, Migliori GB, Cassone A, et al. Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy. Eur Respir J 2012; 39: 1263-1266.
31. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC), 2nd Edn. The Hague, Tuberculosis Coalition for Technical Assistance, 2009.
32. Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J 2012; 39: 807-819.